Search Within

Genitourinary Oncology Service

Formats
  1. Journal Article (2765)
  2. Meeting Abstract (2521)
  3. Review (115)
  4. Book Section (83)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (16)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Solid Tumor Oncology Division (5646)
  2. Department of Medicine (5636)
  3. GSK Faculty (1648)
  4. Human Oncology and Pathogenesis Program (1146)
  5. Department of Pathology and Laboratory Medicine (1041)
  6. Surgery (1009)

More Groups

People
  1. Robert Motzer (1247)
  2. Howard Scher (1130)
  3. David Solit (781)
  4. Dean Bajorin (660)
  5. Michael Morris (583)
  6. Jonathan Rosenberg (519)

More People

Years
  1. 2025 (155)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1712)
  2. Annals of Oncology (304)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (119)

More Publications

Publishers
  1. American Society of Clinical Oncology (1775)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (411)
  4. Elsevier Science, Inc. (390)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (296)

More Publishers

Results (5646)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Olaparib and durvalumab in patients with DNA damage repair alterations and biochemically recurrent prostate cancer
    Journal Article

    Autio, K. A.; McHugh, D. J.; Rathkopf, D. E.; Xiao, H.; Merugu, S.; Wong, P.; Jan, M.; Dorff, T. B.; Heath, E. I.; Scher, H. I.
    Journal of Immunotherapy and Precision Oncology (2025)

    Fulltext@MSK | Save
  • Immune checkpoint combos in metastatic castration-resistant prostate cancer: Where are we going, what are we doing, and why?
    Editorial

    Slovin, S. F.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Enfortumab vedotin and pembrolizumab: Redefining the standard of care for previously untreated advanced urothelial cancer
    Review

    Sternschuss, M.; Rosenberg, J. E.
    Future Oncology (2025)

    Fulltext@MSK | Save
  • ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practice
    Guidelines

    Westphalen, C. B.; Boscolo Bielo, L.; Aftimos, P.; Beltran, H.; Benary, M.; Chakravarty, D.; Collienne, M.; Dienstmann, R.; El Helali, A.; Gainor, J.; more...
    Annals of Oncology (2025)

    Fulltext@MSK | Save
  • Oncologic outcomes of retroperitoneal lymph node dissection following first-line chemotherapy for metastatic non-seminomatous germ-cell tumors
    Journal Article

    Matulewicz, R. S.; Baky, F.; Liso, N.; Williams, B. M.; Porwal, S.; Assel, M.; Carver, B. S.; Bajorin, D. F.; Motzer, R. J.; Bosl, G. J.; more...
    Annals of Oncology (2025)

    Fulltext@MSK | Save
  • Sarcoid-like reactions in patients treated with checkpoint inhibitors for advanced solid tumors
    Journal Article

    Nykaza, I.; Murciano-Goroff, Y. R.; Desilets, A.; Harada, G.; Postow, M. A.; Callahan, M. K.; Lee, C. H.; Rudin, C. M.; Kelsen, D. P.; Stadler, Z. K.; more...
    The Oncologist (2025)

    Fulltext@MSK | Save
  • Defining the role of pragmatic clinical trials in cancer clinical research: Outcomes of a collaborative workshop hosted by the European Organisation for Research and Treatment of Cancer
    Journal Article

    Cardoso Borges, F.; van der Graaf, W. T. A.; Saesen, R.; Aebi, S.; Amariutei, A. E.; Bekelman, J.; Gorlia, T.; Hulstaert, F.; Huys, I.; Kluetz, P.; more...
    Lancet Oncology (2025)

    Fulltext@MSK | Save
  • Health-related quality-of-life profile and clinical outcomes in first-line advanced renal cell carcinoma: A modeling analysis based on the CheckMate 9ER study
    Journal Article

    Cella, D.; Derosa, M.; Floden, L.; Giles, R. H.; Lothgren, M.; Ogareva, A.; Powles, T.; Purnajo, I.; Choueiri, T. K.; Bergerot, C.; more...
    ESMO Open (2025)

    Fulltext@MSK | Save
  • A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer
    Journal Article

    Gouda, M. A.; Voss, M. H.; Tawbi, H.; Gordon, M.; Tykodi, S. S.; Lam, E. T.; Vaishampayan, U.; Tannir, N. M.; Chaves, J.; Nikolinakos, P.; more...
    ESMO Open (2025)

    Fulltext@MSK | Save
  • A phase I dose-escalation study of the HIF-2 alpha inhibitor DFF332 in patients with advanced clear-cell renal cell carcinoma
    Journal Article

    Pal, S. K.; Bernard-Tessier, A.; Grell, P.; Gao, X.; Kotecha, R. R.; Picus, J.; de Braud, F.; Takahashi, S.; Wong, A.; Suárez, C.; more...
    Clinical Cancer Research (2025)

    Fulltext@MSK | Save